https://scholars.lib.ntu.edu.tw/handle/123456789/629196
標題: | Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy | 作者: | Liu, Ping-Yen Su, Cheng-Huang Kuo, Feng-Yu Lee, Wen-Lieng YI-CHIH WANG Lin, Wei-Shiang Chu, Pao-Hsien Lu, Tse-Min Lo, Ping-Han Lee, Cheng-Han Lan, Wei-Ren Huang, Chien-Lung Tsukiyama, Shuji Yang, Wei-Chen Cheng, Li-Chung Rafael, Virginia Nikolajsen, Christian Yin, Wei-Hsian |
關鍵字: | Acute coronary syndrome; Antiplatelet; P2Y12 reaction unit; Prasugrel; Regimen switch | 公開日期: | 四月-2022 | 出版社: | SPRINGER JAPAN KK | 卷: | 37 | 期: | 2 | 起(迄)頁: | 269 | 來源出版物: | Cardiovascular intervention and therapeutics | 摘要: | The recommended maintenance dose of prasugrel for East Asian populations (i.e., Japanese and Taiwanese) is 3.75 mg as part of dual antiplatelet therapy (DAPT) for the prevention of recurrent ischemia and stent thrombosis in acute coronary syndrome (ACS). This modified dosage regimen has been established in studies conducted in Japan; however, the efficacy and safety of switching from clopidogrel to prasugrel DAPT among Taiwanese patients remain to be explored. In this phase IV, multicenter, single-arm, open-label study, we evaluated the 4-week pharmacodynamic response, and the 48-week safety outcomes of prasugrel 3.75 mg after a switch from clopidogrel in Taiwanese ACS patients. A total of 203 prasugrel-naïve ACS patients (over 90% male) who had received post-PCI clopidogrel DAPT for at least 2 weeks were enrolled from ten medical centers in Taiwan and subsequently switched to prasugrel 3.75 mg DAPT. Four weeks after the switch, P2Y12 reaction unit (PRU) values were significantly decreased in the total cohort (mean - 18.2 ± 48.1; 95% confidence interval - 24.9 to - 11.5, p < 0.001), and there was an overall consistent antiplatelet response in the treated subjects. The proportion of patients with high on-treatment platelet reactivity (HPR; PRU > 208) dropped from 23.5 to 10% (p < 0.001). Female sex was associated with a greater PRU reduction with prasugrel, whereas HPR at baseline, age ≥ 65 years, and body mass index ≥ 25 best predicted HPR at Week 4. Throughout the 48-week treatment with prasugrel, the incidences of MACE (1.0%) and TIMI major bleeding (2.0%) were rather low, accompanying an acceptable safety profile of TIMI minor (6.4%) and non-major, non-minor clinically relevant bleeding (3.0%). Overall, switching to the maintenance dose of prasugrel (3.75 mg) was observed to be effective and well tolerated among post-PCI ACS patients in Taiwan. Clinical Trial Registration Number: NCT03672097. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/629196 | ISSN: | 1868-4300 | DOI: | 10.1007/s12928-021-00771-w |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。